Prevalence of Covid-19 in Children Admitted to Paediatric Emergency Departments During the Pandemic Period in France
INCOVPED
2 other identifiers
observational
901
1 country
6
Brief Summary
Arriving in December 2019, Coronavirus COVID-19 infection is causing a global pandemic with high morbidity and mortality among adults and especially seniors. The child appears little or no affected by this infection. It is estimated that the child could be asymptomatic or pauci-symptomatic carrier and thus be vector of the disease. For this reason, measures have been taken to close schools and contain populations in a large number of countries, including France. However, there are no data on the prevalence of COVID-19 in children.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started Apr 2020
Shorter than P25 for all trials
6 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
April 3, 2020
CompletedFirst Posted
Study publicly available on registry
April 7, 2020
CompletedStudy Start
First participant enrolled
April 15, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
January 1, 2021
CompletedStudy Completion
Last participant's last visit for all outcomes
January 1, 2021
CompletedMarch 11, 2021
March 1, 2021
9 months
April 3, 2020
March 10, 2021
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Prevalence of positivity of COVID-19 virus measured by rt-PCR
At 28 days
Secondary Outcomes (5)
Prevalence of positivity of COVID-19 virus measured by rt-PCR in the following subpopulations of emergency patients
at the end an average 28 days
Respiratory signs of children tested within 28 day
through study completion, an average 28 days
Percentage of children hospitalized tested within 28 day
through study completion, an average 28 days
Contact frequency
At inclusion
Prevalence of positivity of other respiratory viruses measured by rt-PCR
at 28 days
Study Arms (1)
Child suspected of infection with COVID-19.
Child included with positive included
Interventions
Data collection and nasopharyngeal swab
Eligibility Criteria
Children admitted to hospital pediatric emergencies in France during the pandemic period.
You may qualify if:
- st Line Consultation in Pediatric Emergencies
- All reasons for consultation during working hours
- Informed and written consent of a parent holder (only 1 authorized companion) and a child of understanding age
You may not qualify if:
- Refusal of participation by parents/child of decision age
- No membership of a social security scheme (beneficiary or entitled)
- No understanding of French
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (6)
CH Louis MOURIER
Colombes, France
Hôpital Jeanne de Flandres, CHU
Lille, 59037, France
Hôpital Mère Enfant CHU
Nantes, France
Hôpitaux Pédiatriques de Nice CHU-Lenval
Nice, France
Hôpital des enfants - CHU
Toulouse, France
CHU de Tours
Tours, France
Biospecimen
Nasopharyngeal swab
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
François Dubos, MD,PhD
University Hospital, Lille
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
April 3, 2020
First Posted
April 7, 2020
Study Start
April 15, 2020
Primary Completion
January 1, 2021
Study Completion
January 1, 2021
Last Updated
March 11, 2021
Record last verified: 2021-03